CN111704615B - 咪唑并[1,5-A]吡嗪衍生物作为PI3Kδ抑制剂 - Google Patents
咪唑并[1,5-A]吡嗪衍生物作为PI3Kδ抑制剂 Download PDFInfo
- Publication number
- CN111704615B CN111704615B CN202010273331.8A CN202010273331A CN111704615B CN 111704615 B CN111704615 B CN 111704615B CN 202010273331 A CN202010273331 A CN 202010273331A CN 111704615 B CN111704615 B CN 111704615B
- Authority
- CN
- China
- Prior art keywords
- compound
- optionally substituted
- ring
- alkyl
- substituent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2017/101058 | 2017-09-08 | ||
| CN2017101058 | 2017-09-08 | ||
| CNPCT/CN2017/119373 | 2017-12-28 | ||
| CN2017119373 | 2017-12-28 | ||
| CNPCT/CN2018/086555 | 2018-05-11 | ||
| CN2018086555 | 2018-05-11 | ||
| CN201880057835.7A CN111051312A (zh) | 2017-09-08 | 2018-09-07 | 咪唑并[1,5-A]吡嗪衍生物作为PI3Kδ抑制剂 |
| PCT/CN2018/104559 WO2019047915A1 (en) | 2017-09-08 | 2018-09-07 | IMIDAZO [1,5-A] PYRAZINE DERIVATIVES AS PI3KDELTA INHIBITORS |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880057835.7A Division CN111051312A (zh) | 2017-09-08 | 2018-09-07 | 咪唑并[1,5-A]吡嗪衍生物作为PI3Kδ抑制剂 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111704615A CN111704615A (zh) | 2020-09-25 |
| CN111704615B true CN111704615B (zh) | 2023-02-17 |
Family
ID=65633578
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010273331.8A Active CN111704615B (zh) | 2017-09-08 | 2018-09-07 | 咪唑并[1,5-A]吡嗪衍生物作为PI3Kδ抑制剂 |
| CN201880057835.7A Pending CN111051312A (zh) | 2017-09-08 | 2018-09-07 | 咪唑并[1,5-A]吡嗪衍生物作为PI3Kδ抑制剂 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880057835.7A Pending CN111051312A (zh) | 2017-09-08 | 2018-09-07 | 咪唑并[1,5-A]吡嗪衍生物作为PI3Kδ抑制剂 |
Country Status (21)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX394882B (es) | 2016-12-07 | 2025-03-24 | Beigene Ltd | Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta) |
| NZ761680A (en) | 2017-09-08 | 2023-03-31 | Beigene Ltd | Imidazo[1,5-a]pyrazine derivatives as pi3kdelta inhibitors |
| US20230011916A1 (en) * | 2019-11-21 | 2023-01-12 | Beigene, Ltd. | Methods of cancer treatment using anti-ox40 antibodies in combination with pi3 kinase delta inhibitors |
| JP2024521763A (ja) * | 2021-05-27 | 2024-06-04 | ベイジーン スウィッツァーランド ゲーエムベーハー | Pi3kデルタ阻害剤の塩、その結晶形態、調製方法、及び使用 |
| TW202327611A (zh) * | 2021-09-14 | 2023-07-16 | 英屬開曼群島商百濟神州有限公司 | 使用btk抑制劑和p13激酶抑制劑的組合治療癌症之方法 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005089352A (ja) * | 2003-09-16 | 2005-04-07 | Kissei Pharmaceut Co Ltd | 新規なイミダゾ[1,5−a]ピラジン誘導体、それを含有する医薬組成物およびそれらの用途 |
| CN1898240A (zh) * | 2003-10-15 | 2007-01-17 | Osi制药公司 | 咪唑并吡嗪类酪氨酸激酶抑制剂 |
| CA2922058A1 (en) * | 2013-10-18 | 2015-04-23 | Medivation Technologies, Inc. | Heterocyclic compounds and methods of use |
| AR102220A1 (es) * | 2015-10-08 | 2017-02-15 | Incyte Corp | Imidazopiridinas e imidazopirazinas como inhibidores de lsd1 |
| WO2017216292A1 (en) * | 2016-06-16 | 2017-12-21 | Janssen Pharmaceutica Nv | Bicyclic pyridine, pyrazine, and pyrimidine derivatives as pi3k beta inhibitors |
| WO2018103688A1 (en) * | 2016-12-07 | 2018-06-14 | Beigene, Ltd. | IMIDAZO [1,5-A] PYRAZINE DERIVATIVES AS PI3Kdelta INHIBITORS |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1981890A2 (en) * | 2006-01-25 | 2008-10-22 | OSI Pharmaceuticals, Inc. | UNSATURATED mTOR INHIBITORS |
| EP2419425A4 (en) * | 2009-04-15 | 2012-08-29 | Astrazeneca Ab | IMIDAZOLE SUBSTITUTED PYRIMIDINES USEFUL IN THE TREATMENT OF GLYCOGEN SYNTHASE KINASE 3 RELATED DISORDERS, SUCH AS ALZHEIMER'S DISEASE |
| NZ596185A (en) | 2009-04-16 | 2013-01-25 | Ct Nac Investigaciones Oncologicas Cnio | Imidazopyrazines for use as kinase inhibitors |
| US8653089B2 (en) * | 2011-02-09 | 2014-02-18 | F. Hoffmann-La Roche Ag | Heterocyclic compounds and methods of use |
| CA2860723A1 (en) * | 2012-01-10 | 2013-07-18 | Bayer Intellectual Property Gmbh | Substituted imidazopyrazines as akt kinase inhibitors |
| RU2702908C2 (ru) * | 2012-11-01 | 2019-10-14 | Инфинити Фармасьютикалз, Инк. | Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы |
| TWI736135B (zh) * | 2013-03-01 | 2021-08-11 | 美商英塞特控股公司 | 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途 |
| KR20160013204A (ko) | 2013-05-30 | 2016-02-03 | 인피니티 파마슈티칼스, 인코포레이티드 | Pi3 키나아제 동형단백질 조절제를 사용하는 암의 치료 |
| SMT202100674T1 (it) * | 2014-08-11 | 2022-01-10 | Acerta Pharma Bv | Combinazioni terapeutiche di un inibitore di btk e un inibitore di bcl-2 |
| NZ761680A (en) | 2017-09-08 | 2023-03-31 | Beigene Ltd | Imidazo[1,5-a]pyrazine derivatives as pi3kdelta inhibitors |
-
2018
- 2018-09-07 NZ NZ761680A patent/NZ761680A/en not_active IP Right Cessation
- 2018-09-07 SG SG11202001286SA patent/SG11202001286SA/en unknown
- 2018-09-07 TW TW107131522A patent/TWI817956B/zh not_active IP Right Cessation
- 2018-09-07 EP EP23152036.2A patent/EP4219502A1/en not_active Withdrawn
- 2018-09-07 MX MX2020002630A patent/MX2020002630A/es unknown
- 2018-09-07 CN CN202010273331.8A patent/CN111704615B/zh active Active
- 2018-09-07 CA CA3072842A patent/CA3072842A1/en active Pending
- 2018-09-07 PT PT188532337T patent/PT3679042T/pt unknown
- 2018-09-07 ES ES18853233T patent/ES2944658T3/es active Active
- 2018-09-07 CN CN201880057835.7A patent/CN111051312A/zh active Pending
- 2018-09-07 IL IL272988A patent/IL272988B/en unknown
- 2018-09-07 DK DK18853233.7T patent/DK3679042T3/da active
- 2018-09-07 JP JP2020513700A patent/JP7128264B2/ja active Active
- 2018-09-07 WO PCT/CN2018/104559 patent/WO2019047915A1/en not_active Ceased
- 2018-09-07 KR KR1020207007386A patent/KR20200052297A/ko active Pending
- 2018-09-07 FI FIEP18853233.7T patent/FI3679042T3/fi active
- 2018-09-07 HU HUE18853233A patent/HUE061898T2/hu unknown
- 2018-09-07 PL PL18853233.7T patent/PL3679042T3/pl unknown
- 2018-09-07 US US16/643,040 patent/US11220506B2/en active Active
- 2018-09-07 BR BR112020004500-4A patent/BR112020004500A2/pt not_active Application Discontinuation
- 2018-09-07 EP EP18853233.7A patent/EP3679042B1/en active Active
- 2018-09-07 AU AU2018328569A patent/AU2018328569B2/en not_active Ceased
- 2018-09-07 TW TW111147323A patent/TW202336010A/zh unknown
-
2020
- 2020-02-11 ZA ZA2020/00875A patent/ZA202000875B/en unknown
-
2021
- 2021-11-23 US US17/533,442 patent/US11905294B2/en active Active
-
2023
- 2023-10-25 AU AU2023254925A patent/AU2023254925A1/en not_active Abandoned
-
2024
- 2024-01-11 US US18/410,925 patent/US20240150361A1/en not_active Abandoned
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005089352A (ja) * | 2003-09-16 | 2005-04-07 | Kissei Pharmaceut Co Ltd | 新規なイミダゾ[1,5−a]ピラジン誘導体、それを含有する医薬組成物およびそれらの用途 |
| CN1898240A (zh) * | 2003-10-15 | 2007-01-17 | Osi制药公司 | 咪唑并吡嗪类酪氨酸激酶抑制剂 |
| CA2922058A1 (en) * | 2013-10-18 | 2015-04-23 | Medivation Technologies, Inc. | Heterocyclic compounds and methods of use |
| AR102220A1 (es) * | 2015-10-08 | 2017-02-15 | Incyte Corp | Imidazopiridinas e imidazopirazinas como inhibidores de lsd1 |
| WO2017216292A1 (en) * | 2016-06-16 | 2017-12-21 | Janssen Pharmaceutica Nv | Bicyclic pyridine, pyrazine, and pyrimidine derivatives as pi3k beta inhibitors |
| WO2018103688A1 (en) * | 2016-12-07 | 2018-06-14 | Beigene, Ltd. | IMIDAZO [1,5-A] PYRAZINE DERIVATIVES AS PI3Kdelta INHIBITORS |
Non-Patent Citations (2)
| Title |
|---|
| Imidazo[1,2-a]pyrazines as novel PI3K inhibitors;Sonia Martinez Gonzalez,et al.;《Bioorganic & Medicinal Chemistry Letters》;20120128;第22卷;第1874-1878页 * |
| 选择性PI3Kδ抑制剂的研究进展;辛敏行等;《中国药科大学学报》;20161231;第47卷(第05期);第503-510页 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104918934B (zh) | 3‑取代的吡唑及其作为dlk抑制剂的用途 | |
| CN108368116B (zh) | Janus激酶抑制剂、其组合物及用途 | |
| US11905294B2 (en) | Imidazo[1,5-a]pyrazine derivatives as PI3Kδ inhibitors | |
| CN105566321B (zh) | 杂芳化合物及其在药物中的应用 | |
| US11725012B2 (en) | Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitors | |
| HK40029158B (en) | IMIDAZO[1,5-A]PYRAZINE DERIVATIVES AS PI3Kδ INHIBITORS | |
| HK40029158A (en) | IMIDAZO[1,5-A]PYRAZINE DERIVATIVES AS PI3Kδ INHIBITORS | |
| HK40088309A (en) | Imidazo[1,5-a]pyrazine derivatives as pi3kdelta inhibitors | |
| HK40017128A (en) | Imidazo[1,5-a]pyrazine derivatives as pi3kdelta inhibitors | |
| EA040339B1 (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1,5-а]ПИРАЗИНА КАК ИНГИБИТОРЫ PI3Kδ | |
| HK40029822B (en) | Imidazo[1,5-a]pyrazine derivatives as pi3kdelta inhibitors | |
| HK40029822A (en) | Imidazo[1,5-a]pyrazine derivatives as pi3kdelta inhibitors | |
| HK1258764B (en) | Janus kinases inhibitors, compositions thereof and use thereof | |
| HK1210166B (en) | Fused tricyclic amide compounds as multiple kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40029158 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20251016 Address after: 215002 Jiangsu Province Suzhou City China (Shanghai) Pilot Free Trade Zone Suzhou Area Suzhou Industrial Park Jinhai Road 29.NO Patentee after: Baiji Shenzhou (Suzhou) Biotechnology Co.,Ltd. Country or region after: China Address before: England Group Patentee before: BEIGENE, Ltd. Country or region before: Cayman Islands |
|
| TR01 | Transfer of patent right |